생분해성 스텐트 시장 분석 및 예측(-2035년) : 유형, 제품 유형, 기술, 용도, 재료 유형, 제조 프로세스, 도입 상황, 최종사용자, 기능, 개발 단계

The global Biodegradable Stents Market is projected to grow from $512.2 Million in 2025 to $1428.3 Million by 2035, at a compound annual growth rate (CAGR) of 10.8%. The biodegradable stents market is developing within the broader interventional cardiovascular and minimally invasive device landscape, supported by increasing clinical interest in temporary scaffolding technologies. Demand is shifting toward polymer systems capable of providing sufficient radial strength while progressively resorbing after vascular or luminal healing. Regulatory agencies, including the U.S. Food and Drug Administration and European regulatory frameworks, continue emphasizing biocompatibility, degradation behavior, mechanical integrity, and long-term clinical outcomes for absorbable implants. Industry production is increasingly focused on precision polymer processing, drug-eluting capabilities, radiopacity, and optimized degradation profiles. Commercial momentum remains influenced by clinical evidence, reimbursement conditions, manufacturing scalability, and physician confidence in long-term safety.

Coronary stents represent a major application area, using biodegradable scaffolds to temporarily support narrowed coronary arteries during vascular healing. Peripheral stents address vessels outside the heart, including femoral and iliac arteries, while biliary and ureteral stents maintain drainage pathways in obstructed ducts. Esophageal, gastrointestinal, and tracheal stents provide temporary structural support for luminal strictures, obstruction, or compression. Compared with permanent metallic devices, biodegradable designs aim to provide mechanical support during the critical healing period before progressively degrading, potentially reducing chronic inflammation, late thrombosis, and repeat interventions. Product development increasingly emphasizes controlled degradation, radial strength, deliverability, and application-specific scaffold geometry, supporting broader clinical adoption.

Polylactic acid (PLA), polyglycolic acid (PGA), polycaprolactone (PCL), and polyhydroxyalkanoates (PHA) constitute key biodegradable polymer materials used in stent development. PLA offers favorable biocompatibility, processability, and tunable degradation, making it suitable for vascular scaffolds. PGA provides relatively rapid degradation and high initial strength, although degradation control remains important. PCL degrades more slowly and provides flexibility for applications requiring prolonged support. PHA materials offer biodegradability and biological compatibility with potential for advanced tissue-engineering applications. Material selection depends on degradation kinetics, mechanical performance, molecular structure, inflammatory response, and manufacturing compatibility. Ongoing polymer engineering is improving durability, safety, and controlled bioresorption.

Geographical Overview

North America maintains a substantial position in biodegradable stent development through advanced cardiovascular infrastructure, specialized hospitals, established medical-device manufacturers, and extensive interventional cardiology networks. The United States provides a strong demand base due to cardiovascular disease prevalence, high procedural volumes, sophisticated catheterization facilities, and substantial investment in minimally invasive technologies. Research institutions and device companies continue evaluating bioresorbable polymers, drug delivery, scaffold design, and degradation mechanisms. Regulatory oversight from the U.S. Food and Drug Administration supports structured evaluation of safety and clinical performance. Strong healthcare expenditure, specialized clinical expertise, and established reimbursement systems create favorable conditions for technology development, clinical validation, and selective commercialization.

Europe presents expanding opportunities through established medical-device manufacturing capabilities, academic research networks, and increasing interest in technologies that reduce permanent implant exposure. Countries including Germany, France, the United Kingdom, Italy, and Switzerland support cardiovascular intervention research, advanced polymer engineering, and clinical collaborations. Investments are directed toward bioresorbable scaffolds, drug-eluting systems, precision manufacturing, and next-generation minimally invasive devices. European manufacturers and research institutions are also exploring biodegradable materials for nonvascular applications, broadening potential demand beyond coronary interventions. Harmonized medical-device requirements and increasing emphasis on patient-centered care, sustainable healthcare technologies, and reduced long-term device complications are expected to support continued development and adoption.

Key Trends and Drivers

The Shift Toward Temporary Scaffolding and Natural Vessel Recovery:

The market is moving toward next-generation bioresorbable scaffolds that combine controlled degradation with improved mechanical performance and drug-delivery capabilities. Manufacturers are refining polymer composition, scaffold architecture, surface modification, radiopacity, and manufacturing precision to overcome limitations associated with earlier-generation devices. Development is also expanding beyond coronary applications toward peripheral and nonvascular indications, creating opportunities for application-specific degradation profiles and customized designs. Increasing integration of computational modeling, advanced polymer processing, and tissue-engineering principles is further supporting the development of stents designed to provide temporary structural support while facilitating restoration of natural tissue function.

Rising Demand for Implant-Free Long-Term Vascular Care:

Growing emphasis on minimally invasive treatment and reducing the long-term complications associated with permanent implants is strengthening demand for biodegradable stent technologies. Conventional permanent metallic stents can remain as foreign structures after the treated vessel or lumen has healed, creating potential concerns involving chronic inflammation, restenosis, thrombosis, and limitations for future interventions. Biodegradable stents are designed to provide temporary mechanical support before gradual resorption, aligning with the clinical objective of restoring more natural anatomical function. Increasing cardiovascular and structural disorders, advances in polymer science, improved catheter-based procedures, and expanding research into temporary scaffolding are collectively supporting investment and clinical development.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Material Type
• 2.4 Key Market Highlights by Technology
• 2.5 Key Market Highlights by Application
• 2.6 Key Market Highlights by End User
• 2.7 Key Market Highlights by Process
• 2.8 Key Market Highlights by Functionality
• 2.9 Key Market Highlights by Deployment
• 2.10 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Polymer-based Stents
  • 4.1.2 Metallic Stents
  • 4.1.3 Hybrid Stents
  • 4.1.4 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Coronary Stents
  • 4.2.2 Peripheral Stents
  • 4.2.3 Biliary Stents
  • 4.2.4 Ureteral Stents
  • 4.2.5 Esophageal Stents
  • 4.2.6 Gastrointestinal Stents
  • 4.2.7 Others
• 4.3 Market Size & Forecast by Material Type (2020-2035)
  • 4.3.1 Polylactic Acid (PLA)
  • 4.3.2 Polyglycolic Acid (PGA)
  • 4.3.3 Polycaprolactone (PCL)
  • 4.3.4 Polycarbonate
  • 4.3.5 Polyurethane
  • 4.3.6 Others
• 4.4 Market Size & Forecast by Technology (2020-2035)
  • 4.4.1 Drug-Eluting Stents
  • 4.4.2 Bare-Metal Stents
  • 4.4.3 Bioabsorbable Stents
  • 4.4.4 Others
• 4.5 Market Size & Forecast by Application (2020-2035)
  • 4.5.1 Cardiovascular Diseases
  • 4.5.2 Peripheral Artery Disease
  • 4.5.3 Biliary Disease
  • 4.5.4 Urological Disorders
  • 4.5.5 Gastrointestinal Disorders
  • 4.5.6 Others
• 4.6 Market Size & Forecast by End User (2020-2035)
  • 4.6.1 Hospitals
  • 4.6.2 Ambulatory Surgical Centers
  • 4.6.3 Specialty Clinics
  • 4.6.4 Others
• 4.7 Market Size & Forecast by Process (2020-2035)
  • 4.7.1 Extrusion
  • 4.7.2 Injection Molding
  • 4.7.3 3D Printing
  • 4.7.4 Others
• 4.8 Market Size & Forecast by Functionality (2020-2035)
  • 4.8.1 Self-Expanding Stents
  • 4.8.2 Balloon-Expandable Stents
  • 4.8.3 Others
• 4.9 Market Size & Forecast by Deployment (2020-2035)
  • 4.9.1 Invasive
  • 4.9.2 Non-Invasive
  • 4.9.3 Others
• 4.10 Market Size & Forecast by Stage (2020-2035)
  • 4.10.1 Research and Development
  • 4.10.2 Clinical Trials
  • 4.10.3 Commercialization
  • 4.10.4 Post-Market Surveillance
  • 4.10.5 Others

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Material Type
    • 5.2.1.4 Technology
    • 5.2.1.5 Application
    • 5.2.1.6 End User
    • 5.2.1.7 Process
    • 5.2.1.8 Functionality
    • 5.2.1.9 Deployment
    • 5.2.1.10 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Material Type
    • 5.2.2.4 Technology
    • 5.2.2.5 Application
    • 5.2.2.6 End User
    • 5.2.2.7 Process
    • 5.2.2.8 Functionality
    • 5.2.2.9 Deployment
    • 5.2.2.10 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Material Type
    • 5.2.3.4 Technology
    • 5.2.3.5 Application
    • 5.2.3.6 End User
    • 5.2.3.7 Process
    • 5.2.3.8 Functionality
    • 5.2.3.9 Deployment
    • 5.2.3.10 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Material Type
    • 5.3.1.4 Technology
    • 5.3.1.5 Application
    • 5.3.1.6 End User
    • 5.3.1.7 Process
    • 5.3.1.8 Functionality
    • 5.3.1.9 Deployment
    • 5.3.1.10 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Material Type
    • 5.3.2.4 Technology
    • 5.3.2.5 Application
    • 5.3.2.6 End User
    • 5.3.2.7 Process
    • 5.3.2.8 Functionality
    • 5.3.2.9 Deployment
    • 5.3.2.10 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Material Type
    • 5.3.3.4 Technology
    • 5.3.3.5 Application
    • 5.3.3.6 End User
    • 5.3.3.7 Process
    • 5.3.3.8 Functionality
    • 5.3.3.9 Deployment
    • 5.3.3.10 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Material Type
    • 5.4.1.4 Technology
    • 5.4.1.5 Application
    • 5.4.1.6 End User
    • 5.4.1.7 Process
    • 5.4.1.8 Functionality
    • 5.4.1.9 Deployment
    • 5.4.1.10 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Material Type
    • 5.4.2.4 Technology
    • 5.4.2.5 Application
    • 5.4.2.6 End User
    • 5.4.2.7 Process
    • 5.4.2.8 Functionality
    • 5.4.2.9 Deployment
    • 5.4.2.10 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Material Type
    • 5.4.3.4 Technology
    • 5.4.3.5 Application
    • 5.4.3.6 End User
    • 5.4.3.7 Process
    • 5.4.3.8 Functionality
    • 5.4.3.9 Deployment
    • 5.4.3.10 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Material Type
    • 5.4.4.4 Technology
    • 5.4.4.5 Application
    • 5.4.4.6 End User
    • 5.4.4.7 Process
    • 5.4.4.8 Functionality
    • 5.4.4.9 Deployment
    • 5.4.4.10 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Material Type
    • 5.4.5.4 Technology
    • 5.4.5.5 Application
    • 5.4.5.6 End User
    • 5.4.5.7 Process
    • 5.4.5.8 Functionality
    • 5.4.5.9 Deployment
    • 5.4.5.10 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Material Type
    • 5.4.6.4 Technology
    • 5.4.6.5 Application
    • 5.4.6.6 End User
    • 5.4.6.7 Process
    • 5.4.6.8 Functionality
    • 5.4.6.9 Deployment
    • 5.4.6.10 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Material Type
    • 5.4.7.4 Technology
    • 5.4.7.5 Application
    • 5.4.7.6 End User
    • 5.4.7.7 Process
    • 5.4.7.8 Functionality
    • 5.4.7.9 Deployment
    • 5.4.7.10 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Material Type
    • 5.5.1.4 Technology
    • 5.5.1.5 Application
    • 5.5.1.6 End User
    • 5.5.1.7 Process
    • 5.5.1.8 Functionality
    • 5.5.1.9 Deployment
    • 5.5.1.10 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Material Type
    • 5.5.2.4 Technology
    • 5.5.2.5 Application
    • 5.5.2.6 End User
    • 5.5.2.7 Process
    • 5.5.2.8 Functionality
    • 5.5.2.9 Deployment
    • 5.5.2.10 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Material Type
    • 5.5.3.4 Technology
    • 5.5.3.5 Application
    • 5.5.3.6 End User
    • 5.5.3.7 Process
    • 5.5.3.8 Functionality
    • 5.5.3.9 Deployment
    • 5.5.3.10 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Material Type
    • 5.5.4.4 Technology
    • 5.5.4.5 Application
    • 5.5.4.6 End User
    • 5.5.4.7 Process
    • 5.5.4.8 Functionality
    • 5.5.4.9 Deployment
    • 5.5.4.10 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Material Type
    • 5.5.5.4 Technology
    • 5.5.5.5 Application
    • 5.5.5.6 End User
    • 5.5.5.7 Process
    • 5.5.5.8 Functionality
    • 5.5.5.9 Deployment
    • 5.5.5.10 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Material Type
    • 5.5.6.4 Technology
    • 5.5.6.5 Application
    • 5.5.6.6 End User
    • 5.5.6.7 Process
    • 5.5.6.8 Functionality
    • 5.5.6.9 Deployment
    • 5.5.6.10 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Material Type
    • 5.6.1.4 Technology
    • 5.6.1.5 Application
    • 5.6.1.6 End User
    • 5.6.1.7 Process
    • 5.6.1.8 Functionality
    • 5.6.1.9 Deployment
    • 5.6.1.10 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Material Type
    • 5.6.2.4 Technology
    • 5.6.2.5 Application
    • 5.6.2.6 End User
    • 5.6.2.7 Process
    • 5.6.2.8 Functionality
    • 5.6.2.9 Deployment
    • 5.6.2.10 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Material Type
    • 5.6.3.4 Technology
    • 5.6.3.5 Application
    • 5.6.3.6 End User
    • 5.6.3.7 Process
    • 5.6.3.8 Functionality
    • 5.6.3.9 Deployment
    • 5.6.3.10 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Material Type
    • 5.6.4.4 Technology
    • 5.6.4.5 Application
    • 5.6.4.6 End User
    • 5.6.4.7 Process
    • 5.6.4.8 Functionality
    • 5.6.4.9 Deployment
    • 5.6.4.10 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Material Type
    • 5.6.5.4 Technology
    • 5.6.5.5 Application
    • 5.6.5.6 End User
    • 5.6.5.7 Process
    • 5.6.5.8 Functionality
    • 5.6.5.9 Deployment
    • 5.6.5.10 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Abbott Laboratories
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Boston Scientific
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Medtronic
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Biotronik
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Terumo Corporation
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 B. Braun Melsungen
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Elixir Medical Corporation
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 REVA Medical
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Arterius
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Meril Life Sciences
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Amaranth Medical
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Kyoto Medical Planning
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Sahajanand Medical Technologies
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Lepu Medical Technology
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 OrbusNeich
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Cardionovum
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Alvimedica
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 MicroPort Scientific
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 C. R. Bard
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Cook Medical
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us